Ali Al Zahrani
Overview
Explore the profile of Ali Al Zahrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elabd S, Almohareb O, AlJaroudi D, Al Zahrani A, Brema I
Cureus
. 2024 Jan;
16(1):e52191.
PMID: 38222995
Congenital adrenal hyperplasia (CAH) consists of variable disorders of sex determination and differentiation. 17α-hydroxylase deficiency (17OHD) is an uncommon form of those disorders, which is typically characterized by hypertension, hypokalemia,...
2.
Al Zahrani A, Alfakeeh A, Alghareeb W, Bakhribah H, Basulaiman B, Alsuhail A, et al.
East Mediterr Health J
. 2023 Sep;
29(8):657-663.
PMID: 37698221
Background: Complementary and alternative medicine is widely used in Saudi Arabia. One of the common practices is the use of camel urine alone or mixed with camel milk for the...
3.
Al-Anazi A, Alanazi B, Alshanbari H, Masuadi E, Hamed M, Dandachi I, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765601
Epstein Barr Virus (EBV) is implicated in the carcinogenesis of nasopharyngeal carcinoma (NPC) and currently associated with at least 1% of global cancers. The differential prognosis analysis of NPC in...
4.
Al Zahrani A, Alfakeeh A
J Med Case Rep
. 2021 Mar;
15(1):132.
PMID: 33722275
Background: Fibrolamellar hepatocellular carcinoma is a unique tumor of the liver that differs from the classical hepatocellular carcinoma in diagnosis, behavior, and possibly treatment. There is usually absent underlying liver...
5.
Zilov A, Abdelaziz S, Alshammary A, Al Zahrani A, Amir A, Khalil S, et al.
Diabetes Metab Res Rev
. 2019 Apr;
35(7):e3173.
PMID: 31021474
Management guidelines continue to identify metformin as initial pharmacologic antidiabetic therapy of choice for people with type 2 diabetes without contraindications, despite recent randomized trials that have demonstrated significant improvements...
6.
Khalil S, Abdelaziz S, Al Shammary A, Al Zahrani A, Amir A, Elkafrawy N, et al.
Diab Vasc Dis Res
. 2019 Jan;
16(3):213-226.
PMID: 30606039
Most data on the burden of diabetes and prediabetes are from countries where local infrastructure can support reliable estimates of the burden of non-communicable diseases. Countries in the Middle East...
7.
Owaidah T, Saleh M, Alzahrani H, Abu-Riash M, Al Zahrani A, Almadani M, et al.
Adv Hematol
. 2018 Jun;
2018:1858241.
PMID: 29853900
Background: Bleeding disorders vary in prevalence. While some are rare, some can be common in both sexes. Most bleeding disorders manifest as chronic bleeding tendencies or as an increase in...
8.
Babiker A, Gadi I, Al-Jurayyan N, Nemri A, Al Haboob A, Al Boukai A, et al.
BMC Res Notes
. 2014 Nov;
7:783.
PMID: 25371233
Background: Rickets can occur due to Vitamin D deficiency or defects in its metabolism. Three rare genetic types of rickets with different alterations of genes have been reported, including: Vitamin...
9.
Al Zahrani A, Ibrahim N, Al Eid A
J Oncol Pharm Pract
. 2009 Jan;
15(3):183-6.
PMID: 19171551
Rituximab is a chimeric anti-CD20 monoclonal antibody. Its intravenous administration is associated with substantial infusion related-toxicity. Recommended infusion durations are prolonged (average 5-6 h for first infusion and 3-4 h...
10.
Ahmed M, Yousef H, Greer W, Faraz H, Al Sobhi S, Al Zahrani A, et al.
ANZ J Surg
. 2008 Feb;
78(3):139-43.
PMID: 18269475
Background: A clinicopathological analysis and long-term follow up of 32 patients with Hurthle cell neoplasm (HCN) was undertaken to contrast the clinical and histological features between benign versus malignant HCN...